Analysed MBX BIOSCIENCES INC (MBX:NASDAQ) News Sources
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
07-07-2026
yahoo.com
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
07-05-2026
yahoo.com
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
07-05-2026
yahoo.com
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
12-06-2026
yahoo.com
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)
12-06-2026
advfn.com
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
13-07-2026
yahoo.com
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
06-08-2026
yahoo.com
What is the current price of MBX BIOSCIENCES INC (MBX:NASDAQ)?
The current price of MBX BIOSCIENCES INC (MBX:NASDAQ) is $63.
MBX BIOSCIENCES INC (MBX:NASDAQ) absolute price change since previous trading day?
The absolute price change of MBX BIOSCIENCES INC (MBX:NASDAQ) since the previous trading day is $-3.39.
MBX BIOSCIENCES INC (MBX:NASDAQ) percentage price change since previous trading day?
The percentage price change of MBX BIOSCIENCES INC (MBX:NASDAQ) since the previous trading day is -5.1062%.
What is the most recent average sentiment score for MBX BIOSCIENCES INC (MBX:NASDAQ)?
The most recent average sentiment score for MBX BIOSCIENCES INC (MBX:NASDAQ) is 63 out of 100.
What is the most recent average sentiment for MBX BIOSCIENCES INC (MBX:NASDAQ)?
The most recent sentiment for MBX BIOSCIENCES INC (MBX:NASDAQ) is .
SEC-8K** Filing Available For MBX BIOSCIENCES INC (MBX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.